Listen to “RAISING AWARENESS OF AN OFTEN UNDERDIAGNOSED HEART DISEASE DURING HEART MONTH IN FEBRUARY” on Spreaker.
IT’S ESTIMATED THAT BETWEEN 1 IN 200 AND 1 IN 500 PEOPLE IN THE U.S. ARE AFFECTED BY AN OFTEN UNDERDIAGNOSED HEART CONDITION – HYPERTROPHIC CARDIOMYOPATHY (HAI-PR-TROW-FUHK KAAR-DEE-OW-MAI-AA-PUH-THEE) OR H-C-M. WHEN H-C-M CAUSES THE HEART MUSCLE TO GET SO THICK THAT IT BLOCKS OR REDUCES BLOOD FLOW TO THE REST OF THE BODY, IT IS CALLED OBSTRUCTIVE H-C-M.
OBSTRUCTIVE H-C-M SYMPTOMS ARE ALSO COMMON SYMPTOMS OF OTHER DISEASES, WHICH MAKES THE DISEASE HARD TO DIAGNOSE.
JOINING US NOW IS SYMPTOMTIC OBSTRUCTIVE HCM PATIENT STEPHANIE ALONG WITH BOARD CERTIFIED CARDIOLOGIST, DR. WILLIAM CROWDER, TO RAISE AWARENESS OF THIS CONDITION IN HONOR OF HEART MONTH IN FEBRUARY.
Spokesperson Bios
Stephanie, Obstructive HCM Patient
Stephanie is a trained occupational therapist located in Natchez, Mississippi. In 2022, Stephanie was diagnosed with symptomatic obstructive hypertrophic cardiomyopathy, and since then has become passionate about raising awareness of the symptoms and impact of the disease. She is now a part-time yoga teacher who enjoys volunteering, pottery, hiking, walking and spending time with her husband and three sons.
William H. Crowder, MD, board-certified cardiologist, Jackson Heart
Born and raised in Grenada, MS, Dr. Crowder attended Millsaps College where he graduated magna cum laude with a degree in biology. He attended medical school at the University of Mississippi, pursuing training in internal medicine and cardiology. Finally, Dr. Crowder underwent a year of additional training in advanced interventional cardiology techniques at the Medical University of South Carolina. There he trained with national leaders in the interventional cardiology community with an emphasis on atrial septal defect/patent foramen ovale repair as well as techniques for treatment of hypertrophic cardiomyopathy.
He is active in multi-center research trials, staying at the forefront of medical technology.
Dr. Crowder is board certified in internal medicine, cardiovascular disease, and interventional cardiology. His memberships include the Mississippi State Medical Association, the American Medical Association, and the American College of Cardiology. He is a fellow of the College of Cardiology. He has been active in the medical community and is a past member of the board of trustees of the state medical association.
He attends St. Richard’s Church with his wife, Kimberly. When he is not working, he enjoys reading and playing music. He is an accomplished pianist and works with his father on various record projects.
IMPORTANT SAFETY LANGUAGE
This section is for informational purposes only, and should be removed prior to use CAMZYOS CISI 06-15-2023
Indication: Obstructive hypertrophic cardiomyopathy (oHCM)
Last modified on 15/06/2023 08:38:52 PM EST Generated on 05/02/2024 12:20:25 PM EST
INDICATION
CAMZYOS® (mavacamten) is a prescription medicine used to treat adults with symptomatic obstructive hypertrophic cardiomyopathy (HCM). CAMZYOS may improve your symptoms and your ability to be active. It is not known if CAMZYOS is safe and effective in children.
IMPORTANT SAFETY INFORMATION
CAMZYOS (mavacamten) may cause serious side effects, including:
Heart failure, a condition where the heart cannot pump with enough force. Heart failure is a serious condition that can lead to death. You must have echocardiograms before you take your first dose and during your treatment with CAMZYOS to help your healthcare provider understand how your heart is responding to CAMZYOS. People who develop a serious infection or irregular heartbeat have a greater risk of heart failure during treatment with CAMZYOS. Tell your healthcare provider or get medical help right away if you develop new or worsening shortness of breath, chest pain, fatigue, swelling in your legs, a racing sensation in your heart (palpitations), or rapid weight gain.
The risk of heart failure is also increased when CAMZYOS is taken with certain other medications. Tell your healthcare provider about the medicines you take, both prescribed and obtained over-the-counter, before and during treatment with CAMZYOS.
Because of the serious risk of heart failure, CAMZYOS is only available through a restricted program called the CAMZYOS Risk Evaluation and Mitigation Strategy (REMS) Program.
• Your healthcare provider must be enrolled in the CAMZYOS REMS Program in order for you to be prescribed
CAMZYOS.
• Before you take CAMZYOS, you must enroll in the CAMZYOS REMS Program. Talk to your healthcare provider about how to enroll in the CAMZYOS REMS Program. You will be given information about the program when you enroll.
• Before you take CAMZYOS, your healthcare provider and pharmacist will make sure you understand how to
take CAMZYOS safely, which will include returning for echocardiograms when advised by your healthcare provider.
• CAMZYOS can only be dispensed by a certified pharmacy that participates in the CAMZYOS REMS
Program. Your healthcare provider can give you information on how to find a certified pharmacy. You will not be able to get CAMZYOS at a local pharmacy.
• If you have questions about the CAMZYOS REMS Program, ask your healthcare provider, visit
www.CAMZYOSREMS.com, or call 1-833-628-7367.
#risingawareness #heartdisease #drwilliamcrowder #stephanie #heartfailure #medicine #hcm #symptoms #camzyos
